Abstract
Background
Transient changes in the composition of the myocardial extracellular matrix may contribute to the ventricular systolic dysfunction in Stress-induced cardiomyopathy (SIC). We examined the changes in plasma matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) that occur early after the clinical presentation of SIC.
Methods and Results
Ten patients with SIC were enrolled. Plasma concentrations of the six major MMPs (MMP-1,-2,-3,-7,-8,-9) and all 4 tissue inhibitors of MMPs (TIMP-1,-2,-3,-4) were analyzed and compared with data from fifteen control subjects. Within 24 hours of the clinical presentation, SIC patients had lower MMP-1 levels (0.41±0.13 vs 0.70±0.13 pg/mL, p = 0.048) and MMP-8 levels (1.61±0.34 vs 4.84±1.38 pg/mL, p = 0.001) and higher TIMP-4 levels (3.06±0.40 vs 2.16±0.18 pg/mL, p =0.05) compared to control. Seven of nine SIC patients had elevated LV end-diastolic pressures, and all had normal LV end-diastolic dimensions and volumes.
Conclusion
Patients afflicted with SIC had MMPs and TIMPs profiles similar to those described in hypertensive heart disease and diastolic heart failure and different than the profiles following myocardial infarction. Our findings uncovered a unique biomolecular profile in SIC during the first 24 hours of presentation.
Keywords: Metalloproteinases, Cardiomyopathy, Stress, Stress-induced cardiomyopathy
Introduction
Stress-induced cardiomyopathy (SIC), or Takotsubo cardiomyopathy, is a transient systolic dysfunction of the apical and mid segments of the left ventricle in the absence of obstructive coronary artery disease.
SIC is now recognized worldwide as a distinct clinical entity.1–6 It typically occurs in postmenopausal women,7 who present with clinical, electrocardiographic and laboratory findings indistinguishable from those of Acute Coronary Syndrome, usually following an emotional or physically stressful event. Left ventriculography most commonly reveals akinesis, hypokinesis or dyskinesis of the left ventricular mid segment with or without apical involvement. Coronary angiography shows no evidence of obstructive coronary artery disease to account for the clinical presentation.8 With supportive measures and perhaps standard heart failure therapy, most patients achieve resolution of symptoms with recovery of left ventricular function in 1–4 weeks.8 However, this benign course can be complicated in some by dysrhythmias, pulmonary edema, cardiogenic shock and death.9–10
Several lines of evidence suggest that excess catecholamines plays a prominent role in the pathogenesis of SIC.4,11 Among the leading postulated mechanisms are catecholamine-induced coronary artery spasm2–3 and catecholamine-induced direct myocardial injury.11–13 Needless to say, the biomolecular mechanisms involved in the stress-induced myocardial dysfunction have not been fully elucidated.
The extra-cellular matrix (ECM) provides a structural scaffold for cells to differentiate, grow and migrate.14–16 Matrix metalloproteinases (MMPs) are enzymes involved in ECM turnover. Based on their substrate specificity for various ECM components, MMPs are divided into different classes: collagenases (MMPs 1,8 and 13), gelatinases (MMPs 2 and 9), stromelysins (MMPs 3 and 10) and matrilysins (MMPs 7,11 and 26).15 Tissue inhibitors of metalloproteinases (TIMPs) block the action and inhibit the activity of MMPs.16 Under normal conditions, the balanced interaction between MMPs and TIMPs allows for a normal turnover and maintenance of all body tissues including the myocardium. MMPs and TIMPs are involved in several cardiovascular disease processes including atherosclerosis plaque rupture,17,18 acute myocardial infarction,19 LV aneurysm formation and rupture,20 LV remodeling following pressure and/or volume overload,21–27 and age-dependent changes in left ventricular structure.28
Several studies have now demonstrated that unique plasma signatures of MMPs and TIMPs arise in patients with different etiologies of heart failure, and in some cases have been associated with clinical progression of disease.29–32 Thus, the present study tested the hypothesis that the presentation of SIC would result in a significant change in MMP and TIMP plasma profiles.
Methods
Study Population
Ten patients admitted to the Ross Heart Hospital with the clinical presentation of acute coronary syndrome between May 2010 and April 2011 and who met the proposed Mayo criteria8 for SIC were enrolled in the study. The protocol was approved by Institutional Review Board and informed consent was obtained prior to obtaining a blood sample from each subject.
Demographic data, clinical characteristics, left ventriculography and coronary angiography, echocardiography and/or cardiac magnetic resonance imaging, and a peripheral blood sample for plasma were obtained on each SIC patient. These studies were performed within 24 hours of arrival in the Emergency Department.
Hypertension was defined as a blood pressure consistently above 140/90mmHg or current treatment with antihypertensive medications. Hyperlipidemia was defined as total cholesterol above 200 mg/dL or current treatment with lipid-lowering agents. Diabetes and chronic obstructive pulmonary disease were considered present based on previous diagnoses by other health-care providers. Stressors were defined as a physical challenge or illness or an emotional event occurring up to 4 weeks preceding the index event. ST segment elevation was defined as deviation more than 1mm higher than baseline in 2 or more contiguous leads. T-wave inversion was defined if present in 2 or more contiguous leads and represented a change from a previous electrocardiogram recording.
Left heart catheterization with coronary angiography was performed in all SIC patients. Echocardiography was performed in eight and cardiac magnetic resonance imaging in six of the SIC patients; all SIC patients had one or the other and four had both imaging modalities. The coronary angiograms, left ventriculograms, echocardiography and cardiac magnetic resonance imaging were reviewed by two cardiologists who agreed that the findings were consistent with the diagnosis of SIC. Normal limits and ranges for LV end-diastolic dimensions (< 5.3 cm) and volumes (96–174 ml) were based on the American Society of Echocardiography guidelines for chamber quantification33 and a key study of normal ventricular dimensions by cardiac magnetic resonance imaging.34
MMPs and TIMPs Measurement/Analysis
Systemic venous blood samples (10 mL) were obtained with the subjects in a resting, supine position for a minimum of 30 minutes. All samples were placed in chilled EDTA tubes, centrifuged, and plasma stored at −70°C until assay. At the time of assay, plasma samples were allowed to thaw on ice, and subjected to multiplex suspension arrays for MMP (LMP000, R&D Systems) and TIMP (LKT003, R&D Systems) measurements in which all samples could be measured simultaneously for multiple MMPs and TIMPs, thereby minimizing inter-assay variability. The multiplex array was previously validated and calibrated using internal controls for each measured MMP and TIMP.35,36 Major classes of MMPs: gelatinases (MMP-2 and MMP-9), collagenase (MMP-1 and 8), stromelysin (MMP-3), and matrilysin (MMP-7); and all 4 tissue inhibitors of MMPs (TIMP-1, -2, -3, -4) were examined. The relative fluorescence obtained for each distinct MMP and TIMP (Bio-Plex 200, BioRad Laboratories) was converted to an absolute concentration using calibration curves generated from known concentrations of recombinant standards. Average sensitivities for MMPs and TIMPs were 5 pg/mL with a coefficient of variation for these assays of 15% or less. Readings from all samples were within the targeted dynamic range defined by the standards. For the purposes of referent normal comparisons, plasma was collected from 15 age and gender matched referent control subjects.
Statistical Analysis
Absolute MMP and TIMP values for the referent normal and SIC patients were first analyzed using the non-parametric Kruskal-Wallis test. Following which, the SIC MMP and TIMP values were determined as a function of referent normal values and expressed as a percent. Significant differences from this analysis were examined using a t-statistic. The statistical procedures were performed using STATA (STATA Intercooled V 8.0. College Station, TX). Values were reported as the mean ± standard error of the mean (SEM) where p values <0.05 were considered statistically significant. Results from all of these statistical analyses are listed in Table 3 and Figure 1.
Table 3.
Plasma levels of MMPs and TIMPs in patients with stress induced cardiomyopathy (SIC) versus normal referent controls
| Analyte (ng/mL) | Normal (n=15) | SIC (n=10) | * (p-value) | † (p-value) |
|---|---|---|---|---|
| MMP-1 | 0.70±0.13 | 0.41±0.13 | 0.047 | 0.048 |
| MMP-2 | 374.82±35.71 | 345.82±30.54 | 0.651 | 0.37 |
| MMP-3 | 10.72±1.64 | 11.35±3.55 | 0.437 | 0.86 |
| MMP-7 | 1.39±0.25 | 1.23±0.28 | 0.640 | 0.58 |
| MMP-8 | 4.84±1.38 | 1.61±0.34 | 0.421 | 0.001 |
| MMP-9 | 121.06±13.12 | 118.41±40.24 | 0.387 | 0.95 |
| TIMP-1 | 106.30±4.40 | 100.44±6.81 | 0.506 | 0.41 |
| TIMP-2 | 73.67±3.33 | 78.48±2.78 | 0.318 | 0.12 |
| TIMP-3 | 3.69±0.38 | 3.51±1.06 | 0.101 | 0.87 |
| TIMP-4 | 2.16±0.18 | 3.06±0.40 | 0.035 | 0.05 |
Kruskal Wallis, non-parametric analysis
% change from referent control
Figure 1.
Percentage change in MMP (matrix metalloproteinase) and TIMP (tissue inhibitor of MMP) levels in patients with Stress-induced cardiomyopathy (SIC) compared with referent controls. The pattern of changes in MMPs and TIMPs suggests a pro-fibrotic profile, one that is clearly different from an acute myocardial infarction. * = p < 0.05 versus referent controls.
Correlation coefficient (Pearson's r values) were determined to assess the relationships between the MMPs and TIMPs versus peak troponin, left ventricular end-diastolic pressure and ejection fraction.
Results
Clinical characteristics
The fifteen referent controls were 9 women and 6 men with a mean age of 59 ± 2 years, and a mean body surface area of 1.8 ± 0.1 Kg/m2. They had a mean heart rate of 68 ± 2 BPM, a mean systolic blood pressure of 125 ± 2 mmHg, and a mean diastolic blood pressure of 74 ± 1 mmHg. All had a normal ECG, echocardiogram and 6 minute hall walk times. Referent controls had a mean LV EDD of 4.4 ± 0.1 cm, and a mean LV EDV of 88.4 ± 6.6 ml. None of the referent controls had a history of, current evidence for, or were being treated for hypertension, diabetes, hyperlipidemia or any cardiovascular disease.
The clinical characteristics of SIC patients are outlined in table 1. All ten SIC patients met the proposed criteria for the diagnosis of SIC. Women represented 90% of the group. Mean Age was 60.3 years. Hypertension was present in 90 % of patients with 50% of patients receiving an angiotensin converting enzyme inhibitor. Chest pain and/or dyspnea were the presenting symptoms in 80% of the study population, and a clearly identified stressor was present in 80%. ST-Segment elevation was present on the index electrocardiogram in 20% of patients, while dynamic T-wave inversion was present in the remaining 80%. Troponin-I elevation was present in all patients with an average peak of 3.316 ng/ml.
Table 1.
Clinical characteristics of patients with stress-induced cardiomyopathy (n=10)
| Demographic | Value | |
|---|---|---|
| Age | 60.3 years | |
| Female | 9 (90%) | |
| Hypertension | 9 (90%) | |
| Hyperlipidemia | 5 (50%) | |
| Diabetes Mellitus | 2 (20 %) | |
| Chronic Obstructive Pulmonary Disease | 1 (10%) | |
| Tobacco Use | Never | 8 (80%) |
| Former | 2 (20 %) | |
| Current | 0 (0%) | |
| Presenting symptom | Chest pain alone | 5(50%) |
| Chest pain and dyspnea | 3 (30%) | |
| Dyspnea alone | 1 (10%) | |
| Confusion | 1 (10 %) | |
| Stressor | Emotional | 8 (80%) |
| Physical | 0 (0%) | |
| No stressor | 2 (20 %) | |
| Medications on admission | ASA | 1 (10 %) |
| Beta Blocker | 2 (20%) | |
| ACE-I | 5 (50 %) | |
| Statin | 1 (10 %) | |
| Admission Electrocardiogram | ST elevation | 2 (20%) |
| T -wave inversion | 8 (80%) | |
| Elevated Troponin I | 10 (100%) | |
The LV end-diastolic dimensions, LV end-diastolic volumes and LV end-diastolic pressures for the SIC patients are presented in table 2. The mean LV end-diastolic dimension on echocardiography was 4.3±0.12cm and the mean LV end-diastolic volume was 85.4 ± 4.6 ml. The mean LV end-diastolic dimension on cardiac magnetic resonance imaging was 4.7±0.2cm and the mean LV end-diastolic volume was 137.8 ± 11.3ml. LV end-diastolic pressure was available in 9 patients and the mean value was 16.9± 1.2 mmHg. All SIC patients had normal LV end-diastolic dimensions and volumes. Seven patients had LV end-diastolic pressures above the upper limit of our normal range, specifically 15, 16, 16 18, 20, 21 and 22 mmHg.
Table 2.
LV end-diastolic dimensions, LV end-diastolic volumes and LV end-diastolic pressures of patients with stress-induced cardiomyopathy
| Patient | LVEDP (mmHg) | LVED Diameter (cm) | LVED Volume (ml) | ||
|---|---|---|---|---|---|
| Echo | MRI | Echo | MRI | ||
| A | 13 | 4.4 | N/A | 68 | N/A |
| B | 18 | 4.7 | N/A | 86 | N/A |
| C | 11 | 4.8 | 4.8 | 106 | 154 |
| D | 20 | 4.2 | 4.2 | 88 | 101 |
| E | N/A | N/A | 5.5 | N/A | 168 |
| F | 21 | 4.3 | N/A | 83 | N/A |
| G | 16 | 4.1 | 4.4 | 80 | 114 |
| H | 22 | 3.5 | 4.6 | 71 | 127 |
| I | 16 | N/A | 4.6 | N/A | 163 |
| J | 15 | 4.7 | N/A | 101 | N/A |
| Mean ± SEM | 16.9± 1.2 | 4.3±0.12 | 4.7±0.2 | 85.4 ± 4.6 | 137.8 ± 11.3 |
MMP and TIMP profiles
Plasma values for MMP-1, -2, -3, -7, -8, -9 and TIMP-1, -2, -3, -4 in the SIC patients and referent controls are shown in columns 2 and 3 respectively in table 3. MMP-12 and -13 did not reach detectable thresholds in the multiplex suspension array, and therefore were excluded from further analysis.
Columns 4 and 5 of table 3 and figure 1 present the differences between SIC patients and referent controls in MMP and TIMP values for this study. SIC patients had a significant reduction in plasma MMP-1 and MMP-8 compared with the referent control subjects (both p< 0.05). MMP-1 was reduced by a relative 40%, MMP-8 was reduced by 60%. The remainder of the MMPs measured (MMP-2, MMP-3, MMP-7 and MMP-9) were not significantly different from the referent control subjects.
SIC patients had a significant increase in plasma TIMP-4 compared with the referent controls (p< 0.05). TIMP-4 increased by a relative 40%. The remainder of the TIMPs (TIMP-1, TIMP-2, and TIMP-3) were unchanged compared with the referent control subjects.
Correlation studies were performed between the MMPs and TIMPs versus peak troponin, left ventricular end-diastolic pressure or ejection fraction. The correlation (r values) were in the - 0.57 to 0.58 range (max r2=0.34) with p values >0.2.
Discussion
The SIC patients in this study had demographic, clinical and laboratory findings similar to those described in previous reports of patients with SIC.1–4 The intent of this study was to examine plasma MMPs and TIMPs levels early in the course of SIC, which may provide insight into the underlying molecular mechanisms causing the LV remodeling and the transient nature of the structural and functional changes that occur in SIC.
We hypothesized that since the LV systolic functional changes with SIC resemble those of myocardial infarction following an acute coronary occlusion, the underlying changes in MMPs and TMPs should be similar and directionally parallel. Contrary to our hypothesis, we found that early in the course of SIC, the collagenases MMP-1 and MMP-8 were significantly decreased and TIMP-4 was significantly increased. This stoichiometric extracellular profile favors the preservation of extracellular collagen structure rather than collagen degradation.
Extracellular changes leading to LV remodeling after myocardial infarction (secondary to coronary artery occlusion) were studied recently, demonstrating an acute rise in plasma MMP-8 and MMP-9 and a significant reduction in TIMP-4 early post infarction.19 Additionally, the levels of MMP-1, MMP-8 and MMP-9 were increased in atheromatous vulnerable plaques compared to fibrous plaques,37,38 and in patients with acute coronary syndromes.39,40 This molecular pattern in the interstitial proteases is distinctly different from that seen in our patients, suggesting differences in the underlying pathophysiologic changes in structure and function. Following an acute myocardial infarction, there is a rapid and sustained increase in LV end-diastolic volume;19 this may be related to the increased protease expression and activity that favor extracellular matrix degradation. By contrast, during SIC, LV end-diastolic volume remains normal, perhaps explained by the decrease in proteases activity. In fact, all patients in this report had normal LV end-diastolic dimensions and volumes. Another control group, namely patients with Acute Coronary Syndrome (ACS), would have been informative.
A number of studies have evaluated changes in the myocardial ECM in hypertensive heart disease and diastolic heart failure. A plasma multibiomarker profile consisting of increased MMP-2 and TIMP-4 and decreased MMP-8 predicted the presence of diastolic heart failure.27 Other studies have demonstrated elevated levels of MMP-2, MMP-9 and TIMP-1 in hypertensive patients with diastolic dysfunction.41,42 Moreover, MMP-1, which degrades collagen type-1 and is inhibited by TIMP-1, was found to be reduced in the blood of patients with hypertension.43 Interestingly, this pro-fibrotic MMP/TIMPS profile seen in hypertensive patients with diastolic dysfunction is very similar to the extracellular profile described in our patients. This may suggest a role for transient LV stiffness or a transient pro-fibrotic state as an underlying mechanism for SIC. Indeed, seven of nine patients in this report had LV end-diastolic pressures above normal and in all patients, the pressures resided above 10 mmHg.
Among the postulated mechanisms for SIC, catecholamine-induced coronary artery spasm2–3 and/or catecholamine-induced direct myocardial injury11–13 are the most widely studied. Plasma catecholamine levels were reported to be considerably higher in patients with SIC as compared to patients with acute myocardial infarction.11 In rats, norepinephrine infusion was associated with increased MMP-2 activity and LV hypertrophy.44–46 In addition, isoproterenol infusion was associated with upregulated MMP-1, MMP-2 and MMP-9 activities, in addition to increased myocardial fibrosis and myocardial cross sectional area.47,48 Similarly, in humans, MMP-2 and MMP-9 levels were significantly elevated in severe heart failure patients and plasma MMP-2 was positively correlated with noradrenaline levels.49 In the same study, exposure of human cardiac fibroblasts to noradrenaline resulted in increased MMP-2 levels. Our findings do not reflect such changes on MMP-2 or MMP-9, at least within 24 hours of clinical presentation of SIC.
Our study has a number of limitations. First, it is a relatively small population of what could turn out to be a more heterogeneous disease. Second, baseline pre-SIC or post-SIC blood samples are not available for comparison. The use of a single measurement in a transient, dynamic disease affecting the complex myocardial ECM may be insufficient. On the other hand, a baseline pre-SIC is not practical or feasible. Third, this study does not provide the direct mechanism for SIC. Nevertheless, this study does provide information on the myocardial cellular responses in SIC, which may then account for the difference in the myocardial behavior and characteristics following SIC, compared to Acute Coronary Syndromes.Lastly, although patients with co-morbidities that could alter the MMP/TIMP levels were excluded, these biomarkers are, at best, surrogates for the regional myocardial matrix changes.
Conclusions
The findings reported uncover a unique profile of serum MMPs and TIMPs in SIC patients 6–24 hours after their clinical presentation.
Acknowledgments
Sources of Funding NIH grants HL094703 and HL096038 (R.J.Gumina), NIH grants HL057952, HL059165 and HL095608 (F.G. Spinale), the Research Service of the Department of Veterans Affairs (M.R. Zile, F.G. Spinale).
Footnotes
Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
The Journal Subject Codes pertaining to the article. : [11] Other heart failure, [108] Other myocardial biology, [3] Acute coronary syndromes
Disclosures No conflicts to disclose
References
- 1.Dote K, Sato H, Tateishi H, Uchida T, Ishihara M. Myocardial stunning due to simultaneous multivessel coronary spasms: a review of 5 cases. J Cardiol. 1991;21:203–14. [PubMed] [Google Scholar]
- 2.Sharkey SW, Lesser JR, Zenovich AG, Maron MS, Lindberg J, Longe TF, et al. Acute and reversible cardiomyopathy provoked by stress in women from the United States. Circulation. 2005;111:472–9. doi: 10.1161/01.CIR.0000153801.51470.EB. [DOI] [PubMed] [Google Scholar]
- 3.Bybee KA, Prasad A, Barsness GW, Lerman A, Jaffe AS, Murphy JG, et al. Clinical characteristics and thrombolysis in myocardial infarction frame counts in women with transient left ventricular apical ballooning syndrome. Am J Cardiol. 2004;94:343–6. doi: 10.1016/j.amjcard.2004.04.030. [DOI] [PubMed] [Google Scholar]
- 4.Dec GW. Recognition of the apical ballooning syndrome in the United States. Circulation. 2005;111:388–90. doi: 10.1161/01.CIR.0000155234.69439.E4. [DOI] [PubMed] [Google Scholar]
- 5.Desmet WJ, Adriaenssens BF, Dens JA. Apical ballooning of the left ventricle: first series in white patients. Heart. 2003;89:1027–31. doi: 10.1136/heart.89.9.1027. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Pavin D, Le Breton H, Daubert C. Human stress cardiomyopathy mimicking acute myocardial syndrome. Heart. 1997;78:509–11. doi: 10.1136/hrt.78.5.509. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Bybee KA, Kara T, Prasad A, Lerman A, Barsness GW, Wright RS, et al. Systematic review: transient left ventricular apical ballooning: a syndrome that mimics ST-segment elevation myocardial infarction. Ann Intern Med. 2004;141:858–65. doi: 10.7326/0003-4819-141-11-200412070-00010. [DOI] [PubMed] [Google Scholar]
- 8.Prasad A, Lerman A, Rihal CS. Apical ballooning syndrome (Tako-Tsubo or stress cardiomyopathy): a mimic of acute myocardial infarction. Am Heart J. 2008;155:408–17. doi: 10.1016/j.ahj.2007.11.008. [DOI] [PubMed] [Google Scholar]
- 9.Bybee KA, Prasad A. Stress-related cardiomyopathy syndromes. Circulation. 2008;118:397–409. doi: 10.1161/CIRCULATIONAHA.106.677625. [DOI] [PubMed] [Google Scholar]
- 10.Akashi YJ, Goldstein DS, Barbaro G, Ueyama T. Takotsubo cardiomyopathy: a new form of acute, reversible heart failure. Circulation. 2008;118:2754–62. doi: 10.1161/CIRCULATIONAHA.108.767012. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Wittstein IS, Thiemann DR, Lima JA, Baughman KL, Schulman SP, Gerstenblith G, et al. Neurohumoral features of myocardial stunning due to sudden emotional stress. N Engl J Med. 2005;352:539–48. doi: 10.1056/NEJMoa043046. [DOI] [PubMed] [Google Scholar]
- 12.Nef HM, Möllmann H, Kostin S, Troidl C, Voss S, Weber M, et al. Tako-Tsubo cardiomyopathy: intraindividual structural analysis in the acute phase and after functional recovery. Eur Heart J. 2007;28:2456–64. doi: 10.1093/eurheartj/ehl570. [DOI] [PubMed] [Google Scholar]
- 13.Ibanez B, Navarro F, Cordoba M, M-Alberca P, Farre J. Tako-tsubo transient left ventricular apical ballooning: is intravascular ultrasound the key to resolve the enigma? Heart. 2005;91:102–4. doi: 10.1136/hrt.2004.035709. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Scott-Burden T. Extracellular matrix: the cellular environment. NiPS. 1994;9:110–115. [Google Scholar]
- 15.Nagase H, Visse R, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res. 2006;69:562–73. doi: 10.1016/j.cardiores.2005.12.002. [DOI] [PubMed] [Google Scholar]
- 16.Brew K, Dinakarpandian D, Nagase H. Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta. 2000;1477:267–83. doi: 10.1016/s0167-4838(99)00279-4. [DOI] [PubMed] [Google Scholar]
- 17.Galis ZS, Sukhova GK, Lark MW, Libby P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493–503. doi: 10.1172/JCI117619. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Galis ZS, Khatri JJ. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res. 2002;90:251–62. [PubMed] [Google Scholar]
- 19.Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, et al. Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: relation to left ventricular remodeling. Circulation. 2006;114:1020–7. doi: 10.1161/CIRCULATIONAHA.105.600353. [DOI] [PubMed] [Google Scholar]
- 20.Carmeliet P. Proteinases in cardiovascular aneurysms and rupture: targets for therapy? J Clin Invest. 2000;105:1519–20. doi: 10.1172/JCI10242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Nagatomo Y, Carabello BA, Coker ML, McDermott PJ, Nemoto S, Hamawaki M, et al. Differential effects of pressure or volume overload on myocardial MMP levels and inhibitory control. Am J Physiol Heart Circ Physiol. 2000;278:H151–61. doi: 10.1152/ajpheart.2000.278.1.H151. [DOI] [PubMed] [Google Scholar]
- 22.Chancey AL, Brower GL, Peterson JT, Janicki JS. Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation. 2002;105:1983–8. doi: 10.1161/01.cir.0000014686.73212.da. [DOI] [PubMed] [Google Scholar]
- 23.Cox MJ, Sood HS, Hunt MJ, Chandler D, Henegar JR, Aru GM, et al. Apoptosis in the left ventricle of chronic volume overload causes endocardial endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol. 2002;282:H1197–205. doi: 10.1152/ajpheart.00483.2001. [DOI] [PubMed] [Google Scholar]
- 24.Kim HE, Dalal SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J. Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest. 2000;106:857–66. doi: 10.1172/JCI8040. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Stroud JD, Baicu CF, Barnes MA, Spinale FG, Zile MR. Viscoelastic properties of pressure overload hypertrophied myocardium: effect of serine protease treatment. Am J Physiol Heart Circ Physiol. 2002;282:H2324–35. doi: 10.1152/ajpheart.00711.2001. [DOI] [PubMed] [Google Scholar]
- 26.Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence of cardiac form and function. Physiol Rev. 2007;87:1285–342. doi: 10.1152/physrev.00012.2007. [DOI] [PubMed] [Google Scholar]
- 27.Zile MR, Desantis SM, Baicu CF, Stroud RE, Thompson SB, McClure CD, et al. Plasma biomarkers that reflect determinants of matrix composition identify the presence of left ventricular hypertrophy and diastolic heart failure. Circ Heart Fail. 2011;4:246–56. doi: 10.1161/CIRCHEARTFAILURE.110.958199. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Lindsey ML, Goshorn DK, Squires CE, Escobar GP, Hendrick JW, Mingoia JT, et al. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc Res. 2005;66:410–9. doi: 10.1016/j.cardiores.2004.11.029. [DOI] [PubMed] [Google Scholar]
- 29.Yarbrough WM, Mukherjee R, Ikonomidis JS, Zile MR, Spinale FG. Myocardial remodeling with aortic stenosis and after aortic valve replacement: Mechanisms and future prognostic implications. J Thorac Cardiovasc Surg. 2011 Jul 13; doi: 10.1016/j.jtcvs.2011.04.044. Epub ahead of print. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Tayebjee MH, Nadar SK, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 levels in patients with hypertension: relationship to tissue Doppler indices of diastolic relaxation. Am J Hypertens. 2004;17:770–774. doi: 10.1016/j.amjhyper.2004.06.023. [DOI] [PubMed] [Google Scholar]
- 31.Tayebjee MH, Nadar S, Blann AD, Gareth Beevers D, MacFadyen RJ, Lip GY. Matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in hypertension and their relationship to cardiovascular risk and treatment: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Am J Hypertens. 2004;17:764–769. doi: 10.1016/j.amjhyper.2004.05.019. [DOI] [PubMed] [Google Scholar]
- 32.Tayebjee MH, Lim HS, Nadar S, MacFadyen RJ, Lip GY. Tissue inhibitor of metalloproteinse-1 is a marker of diastolic dysfunction using tissue Doppler in patients with type 2 diabetes and hypertension. Eur J Clin Invest. 2005;35:8–12. doi: 10.1111/j.1365-2362.2005.01438.x. [DOI] [PubMed] [Google Scholar]
- 33.Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the ChamberQuantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18:1440–63. doi: 10.1016/j.echo.2005.10.005. [DOI] [PubMed] [Google Scholar]
- 34.Alfakih K, Plein S, Thiele H, Jones T, Ridgway JP, Sivananthan MU. Normal human left and right ventricular dimensions for MRI as assessed by turbo gradient echo and steady-state free precession imaging sequences. J Magn Reson Imaging. 2003;17(3):323–9. doi: 10.1002/jmri.10262. [DOI] [PubMed] [Google Scholar]
- 35.Ahmed SH, Clark LL, Pennington WR, Webb CS, Bonnema DD, Leonardi AH, et al. Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation. 2006;113:2089–96. doi: 10.1161/CIRCULATIONAHA.105.573865. [DOI] [PubMed] [Google Scholar]
- 36.Bonnema DD, Webb CS, Pennington WR, Stroud RE, Leonardi AE, Clark LL, et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs) J Card Fail. 2007;13:530–40. doi: 10.1016/j.cardfail.2007.04.010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Alsheikh-Ali AA, Kitsios GD, Balk EM, Lau J, Ip S. The vulnerable atherosclerotic plaque: scope of the literature. Ann Intern Med. 2010;153:387–95. doi: 10.7326/0003-4819-153-6-201009210-00272. [DOI] [PubMed] [Google Scholar]
- 38.Sluijter JP, Pulskens WP, Schoneveld AH, Velema E, Strijder CF, Moll F, et al. Matrix metalloproteinase 2 is associated with stable and matrix metalloproteinases 8 and 9 with vulnerable carotid atherosclerotic lesions: a study in human endarterectomy specimen pointing to a role for different extracellular matrix metalloproteinase inducer glycosylation forms. Stroke. 2006;37:235–9. doi: 10.1161/01.STR.0000196986.50059.e0. [DOI] [PubMed] [Google Scholar]
- 39.Wang J, Xu D, Wu X, Zhou C, Wang H, Guo Y, et al. Polymorphisms of matrix metalloproteinases in myocardial infarction: a meta-analysis. Heart. 2011;97:1542–6. doi: 10.1136/heartjnl-2011-300342. [DOI] [PubMed] [Google Scholar]
- 40.Gopcevic K, Rovcanin B, Kekic D, Radenkovic S. Matrix metalloproteinases and membrane damage markers in sera of patients with acute myocardial infarction. Mol Cell Biochem. 2011;350:163–8. doi: 10.1007/s11010-010-0694-0. [DOI] [PubMed] [Google Scholar]
- 41.Martos R, Baugh J, Ledwidge M, O'Loughlin C, Conlon C, Patle A, et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation. 2007;115:888–95. doi: 10.1161/CIRCULATIONAHA.106.638569. [DOI] [PubMed] [Google Scholar]
- 42.González A, López B, Querejeta R, Zubillaga E, Echeverría T, Díez J. Filling pressures and collagen metabolism in hypertensive patients with heart failure and normal ejection fraction. Hypertension. 2010;55:1418–24. doi: 10.1161/HYPERTENSIONAHA.109.149112. [DOI] [PubMed] [Google Scholar]
- 43.Laviades C, Varo N, Fernández J, Mayor G, Gil MJ, Monreal I, et al. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation. 1998;98:535–40. doi: 10.1161/01.cir.98.6.535. [DOI] [PubMed] [Google Scholar]
- 44.Briest W, Hölzl A, Rassler B, Deten A, Leicht M, Baba HA, et al. Cardiac remodeling after long term norepinephrine treatment in rats. Cardiovasc Res. 2001;52:265–73. doi: 10.1016/s0008-6363(01)00398-4. [DOI] [PubMed] [Google Scholar]
- 45.Chiu YT, Cheng CC, Lin NN, Hung YW, Chen YT, Hsu SL, et al. High-dose norepinephrine induces disruption of myocardial extracellular matrix and left ventricular dilatation and dysfunction in a novel feline model. J Chin Med Assoc. 2006;69:343–50. doi: 10.1016/S1726-4901(09)70271-0. [DOI] [PubMed] [Google Scholar]
- 46.Barth W, Deten A, Bauer M, Reinohs M, Leicht M, Zimmer HG. Differential remodeling of the left and right heart after norepinephrine treatment in rats: studies on cytokines and collagen. J Mol Cell Cardiol. 2000;32:273–84. doi: 10.1006/jmcc.1999.1075. [DOI] [PubMed] [Google Scholar]
- 47.Miura S, Ohno I, Suzuki J, Suzuki K, Okada S, Okuyama A, et al. Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by beta-adrenergic stimulation in rats. J Cardiovasc Pharmacol. 2003;42:174–81. doi: 10.1097/00005344-200308000-00004. [DOI] [PubMed] [Google Scholar]
- 48.Hori Y, Kunihiro S, Sato S, Yoshioka K, Hara Y, Kanai K, et al. Doxycycline attenuates isoproterenol-induced myocardial fibrosis and matrix metalloproteinase activity in rats. Biol Pharm Bull. 2009;32:1678–82. doi: 10.1248/bpb.32.1678. [DOI] [PubMed] [Google Scholar]
- 49.Banfi C, Cavalca V, Veglia F, Brioschi M, Barcella S, Mussoni L, et al. Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. Eur Heart J. 2005;26:481–8. doi: 10.1093/eurheartj/ehi073. [DOI] [PubMed] [Google Scholar]

